Pipeline

PIPELINE

Optimized and Genetically-Engineered TIL Therapies

Our optimized TIL therapies leverage our platform for TIL manufacturing, which has been designed to improve the scalability, logistics, and accessibility of TIL therapy. We are also developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform.

Optimized TIL
Candidate Indication Discovery IND-Enabling Phase 1 Phase 2/3
ITIL-168 Melanoma
ITIL-168 NSCLC
ITIL-168 HNSCC
ITIL-168 Cervical Cancer
ITIL-168 CSCC
CoStAR-TIL
Candidate Indication Discovery IND-Enabling Phase 1 Phase 2/3
ITIL-306 GYN, NSCLC, Other

CSCC: cutaneous squamous cell carcinoma; NSCLC: non-small cell lung cancer; HNSCC: head and neck squamous cell carcinoma; GYN: gynecological malignancies